Search General Info
Search Education
Search Partnering Companies
Next Generation Orphan Drug Incentives
4:30 PM - 5:25 PM (PDT), Monday, June 8, 2020
June 10-18, 2021
Search General Info
Search Education
Search Partnering Companies
The promise of gene and cell therapies, advances in genetic screening and related diagnostics, and precision medicine has generated widespread enthusiasm throughout the rare disease community. At the same time, new patient-focused drug development is giving patient groups a pathway to new treatments. Yet, despite advances, 95% of rare diseases still do not have a treatment.
With Congress considering ways to update the 21st Century Cures Act and new studies imagining future scenarios, this session will explore new approaches to incentives and patient collaboration to foster a new era in orphan drug development for the 30 million Americans suffering with a rare disease.
With Congress considering ways to update the 21st Century Cures Act and new studies imagining future scenarios, this session will explore new approaches to incentives and patient collaboration to foster a new era in orphan drug development for the 30 million Americans suffering with a rare disease.
Sponsored By

Moderator
Speakers
Explore BIO
BIO DOUBLE HELIX SPONSORS







BIO HELIX SPONSORS



1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200
© BIO 2021 All Rights Reserved